Opioids Painkillers Addiction

Un nuevo analgésico no adictivo con menos efectos secundarios


Los investigadores descubrieron que el compuesto benciloxi-ciclopentiladenosina era un analgésico potente en los sistemas modelo de prueba.

Se ha descubierto un nuevo y prometedor analgésico no opioide (analgésico), con menos efectos secundarios potenciales que otros analgésicos potentes.

Un equipo de investigadores dirigido por científicos de la Facultad de Ciencias de la Vida de la Universidad de Warwick ha analizado un compuesto conocido como BnOCPA (benciloxi-ciclopentiladenosina) que se descubrió que es un analgésico potente y selectivo que no es adictivo en los sistemas modelo de prueba. BnOCPA también tiene un modo de acción único, que podría proporcionar un nuevo camino para la creación de fármacos analgésicos.

El estudio, realizado por el equipo de Warwick en colaboración con investigadores de la Universidad de Berna, la Universidad de Cambridge, la Universidad de Coventry, la Universidad de Monash y organizaciones industriales, se publicó recientemente en la revista

In the UK, between a third and a half of the population report having chronic pain that is either moderately or severely disabling. Such pain negatively affects the quality of life, and many of the often prescribed painkillers have side effects. Opioids, such as morphine and oxycodone, can cause addiction and are dangerous when used in excess. There is thus an unmet need for new, powerful painkillers.

Many drug works by activating adapter molecules known as G proteins on the cell surface. The activation of G proteins can cause a variety of cellular effects. Because just one kind of G protein is activated by BnOCPA, its actions are very selective, minimizing the possibility of negative side effects.

Dr. Mark Wall, from the School of Life Sciences at the University of Warwick, who led the research stated: “The selectivity and potency of BnOCPA make it truly unique and we hope that with further research it will be possible to generate potent painkillers to help patients cope with chronic pain.”

Professor Bruno Frenguelli, principal investigator on the project, from the University of Warwick’s School of Life Sciences, added: “This is a fantastic example of serendipity in science. We had no expectations that BnOCPA would behave any differently from other molecules in its class, but the more we looked into BnOCPA we discovered properties that had never been seen before, and which may open up new areas of medicinal chemistry.”

Professor Graham Ladds, co-principal investigator on the project, from the University of Cambridge, said: “This is an amazing story looking at agonist bias for a GPCR. Not only does BnOCPA have the potential to be a new type of painkiller, but it has shown us a new method for targeting other GPCRs in drug discovery.”

Reference: “Selective activation of Gαob by an adenosine A1 receptor agonist elicits analgesia without cardiorespiratory depression” by Mark J. Wall, Emily Hill, Robert Huckstepp, Kerry Barkan, Giuseppe Deganutti, Michele Leuenberger, Barbara Preti, Ian Winfield, Sabrina Carvalho, Anna Suchankova, Haifeng Wei, Dewi Safitri, Xianglin Huang, Wendy Imlach, Circe La Mache, Eve Dean, Cherise Hume, Stephanie Hayward, Jess Oliver, Fei-Yue Zhao, David Spanswick, Christopher A. Reynolds, Martin Lochner, Graham Ladds, and Bruno G. Frenguelli, 18 July 2022, Nature Communications.
DOI: 10.1038/s41467-022-31652-2

Deja un comentario

Tu dirección de correo electrónico no será publicada.